http://rdf.ncbi.nlm.nih.gov/pubchem/patent/CA-1189508-A
Outgoing Links
| Predicate | Object |
|---|---|
| assignee | http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_27a71ddaaa2f5a8c228fc6cb3f3b3098 |
| classificationCPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07D257-06 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07C279-28 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07D295-096 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07D249-14 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07D239-47 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07D471-04 |
| classificationIPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07D249-14 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07D471-04 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07D239-46 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07D295-096 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07C279-28 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07D257-06 |
| filingDate | 1982-07-23-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| grantDate | 1985-06-25-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor | http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_588af27c7555bdd7fc0d04ec816dc42c http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_3e5d8324ccc10b9d5cd31e1c01f3f50c http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_ce6e48211260976a3ed89401868b14ae http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_985dac670a26788b6545ee6e1d087daf http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_33ea2f69a5c0dca47f4fa50de77547a5 |
| publicationDate | 1985-06-25-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber | CA-1189508-A |
| titleOfInvention | Heterocyclic derivatives as histamine h.sub.2- antagonists |
| abstract | ABSTRACT OF THE DISCLOSURE The invention relates to compounds of the general formula (I) (I) and physiologically acceptable salts, hydrates and bioprecursors thereof, in which R1 represents hydrogens, C1-14 alkyl, cycloalkyl, alkenyl, alkynyl, aralkyl, trifluoroalkyl, heteroaralkyl or alkyl substituted by cycloalkyl, hydroxy, alkoxy, amino, alkylamino or dialkylamino; and R2 represents hydrogen or C1-4 alkyl group; or R1 and R2 together with the nitrogen atom to which they are attached form a 5 to 10 membered ring which may be saturated or may contain at least one double bond, may be unsubstituted or may be substituted by one or more C1-3 alkyl groups or a hydroxy group and/or may contain another heteroatom selected from oxygen or sulphur: Alk represents a straight or branched alkylene chain of l to 3 carbon atoms; Q represents a benzene ring in which incorporation into the rest of the molecule is through bonds at the 1-and 3- or 1- and 4- positions: R5 represents hydrogen or acyl; n and m, which may be the same or different, are each 1 or 2; R3 represents hydrogen, alkyl, alkenyl, aralkyl, hydroxy C2-6 alkyl, alkoxy C2-6 alkyl or C1-4 alkanoyloxy C2-6 alkyl; and R7 represents hydrogen, alkyl, alkenyl, aralkyl, acyloxyalkyl, alkylthioalkyl, arylthioalkyl, aryloxyalkyl, aralkyloxyalkyl, or the group (CH2)qR6 where q is zero, 1, 2, 3, 4, 5 or 6 and the alkylene chain (CH2)q may be straight or branched, and R6 is hydroxy, alkoxy, nitro, heteroaryl, tetra-hydropyranyloxy or CH2NHC(=X)NHR9 where X represents NCN, Abstract continued... NSO2 Methyl, NSO2 Phenyl or CHNO2 and R9 is alkyl; or R6 is the group NR10R11, where R10 is hydrogen or alkyl; and R11 is hydrogen, alkyl, alkenyl, aryl, aralkyl, or heteroaralkyl, or R11 is the group SO2R12 where R12 is alkyl or aryl; or R11 is the group COR13 where R13 is hydrogen, alkyl, aryl, aralkyl, alkoxy, halo-methyl, heteroaryl, heteroaralkyl or the group NHR14 where R14 is hydrogen, alkyl, cycloalkylr aryl or aralkyl; or R10 and R11 together represent the group =CR15R16 where R15 represents aryl or heteroaryl and R16 represents hydrogen or alkyl; or R6 is the group SO2R17 in which R17 is hydroxy, alkyl, aryl or the group NR18R19 where R18 and R19, which may be the same or different, each represent hydrogen or alkyl; or R6 is the group COR20 where R20 is hydrogen, hydroxy, alkoxy, aryloxy, aralkyloxy, alkyl, aryl, aralkyl or the group NR21R22 where R21 is hydrogen or alkyl optionally substituted by a hydroxy or alkoxy group; and R22 is hydrogen, alkyl (optionally substituted by a hydroxy or alkoxy group), alkenyl, aryl, aralkyl or cycloalkyl, or NR21R22 forms a 5 to 8 membered ring which may contain another heteroatom, e.g. oxygen, or a double bond and/or may be substituted by hydroxy or one or two C1-3 alkyl groups or R6 is the group CR23=NR24 where R23 is hydrogen, alkyl, aryl or aralkyl and R24 is hydroxy, alkoxy, aralkyl-oxy or -NHC(=Y)NH2 where Y is oxygen or sulphur; or when A represents CR7 and B represents N, the groups R3 and R7 taken together represent or -(CH2)4-; with the proviso that when the group R6 contains a carbon atom through which it is linked to the alkylene group (CH2)q then the total number of carbon atoms in the resulting chain is not greater than 6 (i.e. q is not greater than 5). The compounds show pharmacological activity as selective histamine H2-antagonists. |
| priorityDate | 1982-02-25-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type | http://data.epo.org/linked-data/def/patent/Publication |
Incoming Links
Total number of triples: 108.